The initiation of legal proceedings for discovery of documents from Ranbaxy had sent the media into a spin about whether the development would enable Dai-ichi to back off from the agreement with Ranbaxy promoters and whether the open offer to the public would still stand. Of course, the agreement had always been announced as being a binding one and the ongoing dispute that Ranbaxy had with the UFDA too was public knowledge.
Yet the stock price crashed and then shot back up after the promoters clarified that the agreement was a binding one
